Cancer molecular targets

Our group is focused on the molecular mechanisms driving cancer progression, with particular emphasis in pancreatic cancer. This tumor, in particular pancreatic ductal adenocarcinoma (PDAC), is the third-leading cause of cancer-related death in the developed countries and it is one of the most aggressive human tumors. The 5-year patient survival is less than 2%. Currently, there is no effective therapy for this highly malignant tumor and identification of novel molecular targets is an urgent need. Our group has pioneered several research lines to increase the knowledge about the molecular mechanisms underlying tumor progression and the relevance of tumor-stroma crosstalk in this pathology. Moreover, considering that cancer is a genetic disease caused by changes in gene expression during malignant transformation, we are also very interested in deciphering how these genetic changes are regulated.